

myasthenia gravis, rheumatoid arthritis, diabetes mellitus, systemic lupus erythematosus, multiple sclerosis, autoimmune hemolytic anemia and autoimmune thyroiditis.

Claims 3-8 have been previously cancelled.

9. (Unchanged) The method of claim 1, wherein said treatment suppresses the symptoms of said autoimmune diseases in said human.

Claim 10 has been previously cancelled.

11. (Unchanged) The method of claim 1 wherein said autoantigen is administered orally.

12. (Unchanged) The method of claim 1 wherein said autoantigen is administered enterally.

13. (Unchanged) The method of claim 1 wherein said autoimmune disease is multiple sclerosis.

Claim 14 has been previously cancelled.

15. (Twice Amended) The method of claim 13 wherein said autoantigen is myelin basic protein (MBP), or a biologically active fragment of MBP, wherein said biological activity is the ability to suppress or eliminate T-cell mediated or T-cell dependent autoimmune response.

16. (Unchanged) The method of claim 15 wherein said biologically active fragment of MBP is a non-encephalitogenic fragment of MBP.

17. (Unchanged) The method of claim 16 wherein said non-encephalitogenic fragment of MBP comprises amino acids 1-37 of MBP, or an orally immunosuppressive portion thereof.